Zealand Pharma announces directed issue and private placement of approximately 4.5m new shares
https://www.globenewswire.com/news-release/2022/10/04/2528063/0/en/Zealand-Pharma-announces-directed-issue-and-private-placement-of-approximately-4-5m-new-shares.html
The net proceeds from the Offering are intended to:
• Support the Phase 3 EASE clinical program for glepaglutide and potential regulatory submission for SBS, and pursue a strong strategic partner for future commercialization
• Advance the clinical-stage candidates, including the obesity/metabolic disease portfolio
• Progress additional peptide candidates into early clinical development
• Strengthen the Company’s capital base and cash preparedness (general corporate purposes)
Zealand expects the new funds to provide cash runway until Q2 2024 and expects to advance the clinical pipeline and as such reach several potential key milestones within this time frame.
https://www.globenewswire.com/news-release/2022/10/04/2528063/0/en/Zealand-Pharma-announces-directed-issue-and-private-placement-of-approximately-4-5m-new-shares.html
The net proceeds from the Offering are intended to:
• Support the Phase 3 EASE clinical program for glepaglutide and potential regulatory submission for SBS, and pursue a strong strategic partner for future commercialization
• Advance the clinical-stage candidates, including the obesity/metabolic disease portfolio
• Progress additional peptide candidates into early clinical development
• Strengthen the Company’s capital base and cash preparedness (general corporate purposes)
Zealand expects the new funds to provide cash runway until Q2 2024 and expects to advance the clinical pipeline and as such reach several potential key milestones within this time frame.
4/10 2022 17:30 Aps invest 6
106686 Undrede mig også den faldt tilbage igen efter den gode nyhed....men så fik vi forklaringen :)
5/10 2022 06:53 ProInvestorNEWS 3106692 Zealand Pharma: Gennemfører emission - sikrer sig 786 mio. kr. - GENT
5/10 06:34
Zealand Pharma har tirsdag aften gennemført den rettede emission, som biotekkoncernen tidligere på dagen annoncerede.
Det fremgår af en meddelelse til fondsbørsen.
I alt har selskabet solgt 4.975.000 ordinære aktier og derigennem sikret sig et bruttoprovenu på cirka 786 mio. kr.
Aktierne er solgt til en pris på 158 kr. stykket, hvilket betyder, at der er blevet givet en rabat på 5,4 pct. i forhold til tirsdagens lukkekurs i 167 kr.
Zealand Pharma oplyste tidligere tirsdag, at det ville sælge cirka 4,5 mio. aktier til institutionelle- og professionelle investorer med henblik på at sikre biotekselskabet finansiering frem til og med andet kvartal 2024.
Beslutningen om kapitalforhøjelsen er truffet, efter at Zealand fredag annoncerede positive fase 3-data med sin lægemiddelkandidat Glepaglutid til behandling af korttarmssyndrom, hvilket den dag løftede aktiekursen med 28,5 pct. fra 135,3 kr. til 173,8 kr. Mandag og tirsdag faldt aktien imidlertid lidt tilbage.
De nye aktier ventes at blive noteret og handlet på børsen i København fra den 10. oktober.
.\˙ MarketWire
5/10 06:34
Zealand Pharma har tirsdag aften gennemført den rettede emission, som biotekkoncernen tidligere på dagen annoncerede.
Det fremgår af en meddelelse til fondsbørsen.
I alt har selskabet solgt 4.975.000 ordinære aktier og derigennem sikret sig et bruttoprovenu på cirka 786 mio. kr.
Aktierne er solgt til en pris på 158 kr. stykket, hvilket betyder, at der er blevet givet en rabat på 5,4 pct. i forhold til tirsdagens lukkekurs i 167 kr.
Zealand Pharma oplyste tidligere tirsdag, at det ville sælge cirka 4,5 mio. aktier til institutionelle- og professionelle investorer med henblik på at sikre biotekselskabet finansiering frem til og med andet kvartal 2024.
Beslutningen om kapitalforhøjelsen er truffet, efter at Zealand fredag annoncerede positive fase 3-data med sin lægemiddelkandidat Glepaglutid til behandling af korttarmssyndrom, hvilket den dag løftede aktiekursen med 28,5 pct. fra 135,3 kr. til 173,8 kr. Mandag og tirsdag faldt aktien imidlertid lidt tilbage.
De nye aktier ventes at blive noteret og handlet på børsen i København fra den 10. oktober.
.\˙ MarketWire
5/10 2022 09:02 ProInvestorNEWS 4106701 Company announcement - No. 44 / 2022
Zealand Pharma announces completion of a directed issue and private placement of 4,975,000 new ordinary shares raising gross proceeds of approx. DKK 786 million
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA, JAPAN OR SOUTH AFRICA, EXCEPT AS PERMITTED BY APPLICABLE LAW.
THIS ANNOUNCEMENT IS NOT AN OFFER OF SECURITIES FOR SALE IN THE UNITED STATES AND THE SECURITIES REFERRED TO HEREIN MAY NOT BE OFFERED OR SOLD IN THE UNITED STATES ABSENT REGISTRATION EXCEPT PURSUANT TO AN EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS OF THE U.S. SECURITIES ACT; ANY PUBLIC OFFERING OF SUCH SECURITIES TO BE MADE IN THE UNITED STATES WILL BE MADE BY MEANS OF A PROSPECTUS THAT MAY BE OBTAINED FROM THE ISSUER, WHICH WOULD CONTAIN DETAILED INFORMATION ABOUT THE COMPANY AND MANAGEMENT, AS WELL AS FINANCIAL STATEMENTS.
As announced on 4 October 2022, Zealand Pharma commenced a directed share offering to institutional and professional investors through an accelerated bookbuilding.
Today, 4 October 2022, Zealand Pharma's board of directors has exercised an authorization to increase the share capital by issuing 4,975,000 new shares.
The new shares will be issued at a subscription price of DKK 158 per new share.
The aggregate gross proceeds from the issue will amount to approx. DKK 786 million and Zealand intends to use the net proceeds to help fund continued development of Zealand's proprietary pipeline of investigational peptide-based therapeutics, support pre-commercial activities, and general corporate purposes.
Copenhagen, Denmark, 4 October 2022 - With reference to company announcement no. 43 / 2022 regarding the announcement of a directed issue and private placement of new ordinary shares, Zealand Pharma A/S ("Zealand") (Nasdaq: ZEAL), (CVR-no. 20 04 50 78), a biotechnology company focused on the discovery and development of innovative peptide-based medicines, today announces that the board of directors of Zealand has in accordance with article 7.1 of Zealand's articles of association today exercised an authorization granted by Zealand's annual general meeting held on 6 April 2022, to increase Zealand's share capital by issue of 4,975,000 new ordinary shares (the "New Shares") at a subscription price of DKK 158 per New Share.
The issuance of the New Shares follows an offering at market price in a private placement directed at certain institutional and professional investors in Denmark and certain other jurisdictions (the "Offering"). The subscription price for the New Shares has been determined through an accelerated bookbuilding procedure as part of the Offering.
The Offering is expected to be completed on 7 October 2022 (subject to the satisfaction of customary closing conditions), and the New Shares are expected to be admitted to trading and official listing on Nasdaq Copenhagen on 10 October 2022.
The Offering has not been registered under the U.S. Securities Act of 1933, as amended (the "U.S. Securities Act"), and was made pursuant to applicable exemptions from the obligation to publish a Danish prospectus in Denmark as well as exemptions from the U.S. Securities Act and the securities laws of other applicable jurisdictions, as a directed issue and private placement to eligible institutional and professional investors.
Zealand Pharma announces completion of a directed issue and private placement of 4,975,000 new ordinary shares raising gross proceeds of approx. DKK 786 million
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA, JAPAN OR SOUTH AFRICA, EXCEPT AS PERMITTED BY APPLICABLE LAW.
THIS ANNOUNCEMENT IS NOT AN OFFER OF SECURITIES FOR SALE IN THE UNITED STATES AND THE SECURITIES REFERRED TO HEREIN MAY NOT BE OFFERED OR SOLD IN THE UNITED STATES ABSENT REGISTRATION EXCEPT PURSUANT TO AN EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS OF THE U.S. SECURITIES ACT; ANY PUBLIC OFFERING OF SUCH SECURITIES TO BE MADE IN THE UNITED STATES WILL BE MADE BY MEANS OF A PROSPECTUS THAT MAY BE OBTAINED FROM THE ISSUER, WHICH WOULD CONTAIN DETAILED INFORMATION ABOUT THE COMPANY AND MANAGEMENT, AS WELL AS FINANCIAL STATEMENTS.
As announced on 4 October 2022, Zealand Pharma commenced a directed share offering to institutional and professional investors through an accelerated bookbuilding.
Today, 4 October 2022, Zealand Pharma's board of directors has exercised an authorization to increase the share capital by issuing 4,975,000 new shares.
The new shares will be issued at a subscription price of DKK 158 per new share.
The aggregate gross proceeds from the issue will amount to approx. DKK 786 million and Zealand intends to use the net proceeds to help fund continued development of Zealand's proprietary pipeline of investigational peptide-based therapeutics, support pre-commercial activities, and general corporate purposes.
Copenhagen, Denmark, 4 October 2022 - With reference to company announcement no. 43 / 2022 regarding the announcement of a directed issue and private placement of new ordinary shares, Zealand Pharma A/S ("Zealand") (Nasdaq: ZEAL), (CVR-no. 20 04 50 78), a biotechnology company focused on the discovery and development of innovative peptide-based medicines, today announces that the board of directors of Zealand has in accordance with article 7.1 of Zealand's articles of association today exercised an authorization granted by Zealand's annual general meeting held on 6 April 2022, to increase Zealand's share capital by issue of 4,975,000 new ordinary shares (the "New Shares") at a subscription price of DKK 158 per New Share.
The issuance of the New Shares follows an offering at market price in a private placement directed at certain institutional and professional investors in Denmark and certain other jurisdictions (the "Offering"). The subscription price for the New Shares has been determined through an accelerated bookbuilding procedure as part of the Offering.
The Offering is expected to be completed on 7 October 2022 (subject to the satisfaction of customary closing conditions), and the New Shares are expected to be admitted to trading and official listing on Nasdaq Copenhagen on 10 October 2022.
The Offering has not been registered under the U.S. Securities Act of 1933, as amended (the "U.S. Securities Act"), and was made pursuant to applicable exemptions from the obligation to publish a Danish prospectus in Denmark as well as exemptions from the U.S. Securities Act and the securities laws of other applicable jurisdictions, as a directed issue and private placement to eligible institutional and professional investors.
5/10 2022 11:35 ProInvestorNEWS 4106705 Zealand/CEO: Aktiesalg gør os robuste op til partnerforhandlinger
5/10 11:14
Med stærke fase 3-data i hånden fra et studie med lægemiddelkandidaten Glepaglutid, har Zealand formået at tiltrække stor interesse fra professionelle investorer og har netop sikret sig 786 mio. kr. fra salg af nye aktier.
Pengene skal bruges til at stå stærkt i kommende forhandlinger med en potentiel partner til Glepaglutid og til udvikling af den nuværende pipeline. Det fortæller biotekselskabets topchef, Adam Steensberg, i et interview med MarketWire.
- Jeg vil ikke sætte os selv under pres, for det er et meget vigtigt produkt for os, og man skal ikke forhandle under pres. Og det slipper vi så også for nu, hvor vi har penge på bankbogen og gode data, siger Adam Steensberg.
I alt blev der tirsdag aften solgt knap 5 mio. nye aktier for 158 kr. per styk. Dermed blev der givet en rabat på 5,4 pct. i forhold til tirsdagens lukkekurs i 167 kr. Selv vurderer Zealand, at det med kapitalrejsningen har penge til sit udviklingsarbejde til og med andet kvartal 2024.
- Det giver os en robusthed i forhold til at fokusere på at levere værdi og få skabt de bedste partnerskaber og få drevet vores pipeline frem, siger Adam Steensberg.
FORHANDLINGER OM GLEPAGLUTID NÆSTE ÅR
Han fortæller, at Zealand allerede har indgået fortrolighedsaftaler med flere partneremner til Glepaglutid, men endnu ikke har lukket nogen ind i datarummet.
- Vi har set en enorm interesse, men vi har også været tydelige om, at vi gerne vil have styr på data først og opbygge et stærkt datarum, før vi lukker folk ind.
- Vi vil gerne køre en struktureret proces, og jeg tænker, at det bliver en gang til næste år, at vi åbner den proces, siger Adam Steensberg.
Han har ikke noget hastværk, da Zealand selv er godt klædt på til at håndtere processerne hen mod og også under en registreringsansøgning for Glepaglutid. Desuden har Zealand kompetencerne til at drive det kommercielle arbejde op til en lancering.
Selve registreringsansøgningen venter Zealand at kunne indsende i USA i løbet af andet halvår næste år.
JEFFERIES SPÅR STOR AFTALE
Inden markedsføringsansøgningen sendes, skal Zealand først have langtidsdata fra patienter, der har fået Glepaglutid i op til fire år. Desuden kommer der data fra et mindre studie af lægemiddelkandidaten.
De studier er dog ifølge Adams Steensberg ikke lige så afgørende, som det fase 3-studie, som Zealand kom med data fra i fredags, og som sendte aktien i vejret med 28 pct.
Amerikanske Jefferies vurderede i et notat fredag, at Glepaglutid, der skal tages en til to gange ugentligt, både er mere bekvem, men også formentlig virker bedre, end det nuværende middel på markedet, Gattex, der skal injiceres dagligt mod korttarmssyndrom.
Der er tale om en lidelse, hvor patientens tarm ikke kan optage næringsstoffer og energi i tilstrækkelige mængder, eksempelvis fordi store dele af tyndtarmen er fjernet efter operation, eller fordi tarmen virker utilstrækkeligt efter strålebehandling.
Patienterne har derfor behov for at få tilført ernæring via et drop i blodbanen, såkaldt parenteral ernæring. Med Glepaglutid kan mængden dog nedsættes, og nogle gange kan antallet af gange, hvor der er behov for parenteral ernæring, også reduceres.
Endnu er Glepaglutid og Gattex ikke målt op mod hinanden, men Adam Steensberg glæder sig over, at hele ni patienter, der fik Glepaglutid efter 24 ugers behandling helt kunne stoppe med at få tilført næring via drop. Det tilsvarende tal i studier af Gattex er ifølge Adams Steensberg nul.
Ifølge Jefferies estimater står Zealand med et lægemiddel, der vil kunne sælge for op mod 580 mio. dollar om året, og børshuset regner med, at det kan give anledning til en partneraftale i milliardklassen målt i kroner.
Selv vil Zealand gå efter en aftale, der både giver et stort beløb her og nu, men også indeholder en stor gulerod.
- Det er helt klart vigtigt for mig, at vi får en aftale, hvor der er en stor "upside", men når det er sagt, er det også vigtigt at få en partner, der er maksimalt committet, så jeg kan ikke forestille mig et scenarie, hvor der ikke er en meget stor forudbetaling. Vi kan så måske være klar til at betale nogle af de penge tilbage ind i samarbejdet, siger Adam Steensberg.
.\˙ MarketWire
5/10 11:14
Med stærke fase 3-data i hånden fra et studie med lægemiddelkandidaten Glepaglutid, har Zealand formået at tiltrække stor interesse fra professionelle investorer og har netop sikret sig 786 mio. kr. fra salg af nye aktier.
Pengene skal bruges til at stå stærkt i kommende forhandlinger med en potentiel partner til Glepaglutid og til udvikling af den nuværende pipeline. Det fortæller biotekselskabets topchef, Adam Steensberg, i et interview med MarketWire.
- Jeg vil ikke sætte os selv under pres, for det er et meget vigtigt produkt for os, og man skal ikke forhandle under pres. Og det slipper vi så også for nu, hvor vi har penge på bankbogen og gode data, siger Adam Steensberg.
I alt blev der tirsdag aften solgt knap 5 mio. nye aktier for 158 kr. per styk. Dermed blev der givet en rabat på 5,4 pct. i forhold til tirsdagens lukkekurs i 167 kr. Selv vurderer Zealand, at det med kapitalrejsningen har penge til sit udviklingsarbejde til og med andet kvartal 2024.
- Det giver os en robusthed i forhold til at fokusere på at levere værdi og få skabt de bedste partnerskaber og få drevet vores pipeline frem, siger Adam Steensberg.
FORHANDLINGER OM GLEPAGLUTID NÆSTE ÅR
Han fortæller, at Zealand allerede har indgået fortrolighedsaftaler med flere partneremner til Glepaglutid, men endnu ikke har lukket nogen ind i datarummet.
- Vi har set en enorm interesse, men vi har også været tydelige om, at vi gerne vil have styr på data først og opbygge et stærkt datarum, før vi lukker folk ind.
- Vi vil gerne køre en struktureret proces, og jeg tænker, at det bliver en gang til næste år, at vi åbner den proces, siger Adam Steensberg.
Han har ikke noget hastværk, da Zealand selv er godt klædt på til at håndtere processerne hen mod og også under en registreringsansøgning for Glepaglutid. Desuden har Zealand kompetencerne til at drive det kommercielle arbejde op til en lancering.
Selve registreringsansøgningen venter Zealand at kunne indsende i USA i løbet af andet halvår næste år.
JEFFERIES SPÅR STOR AFTALE
Inden markedsføringsansøgningen sendes, skal Zealand først have langtidsdata fra patienter, der har fået Glepaglutid i op til fire år. Desuden kommer der data fra et mindre studie af lægemiddelkandidaten.
De studier er dog ifølge Adams Steensberg ikke lige så afgørende, som det fase 3-studie, som Zealand kom med data fra i fredags, og som sendte aktien i vejret med 28 pct.
Amerikanske Jefferies vurderede i et notat fredag, at Glepaglutid, der skal tages en til to gange ugentligt, både er mere bekvem, men også formentlig virker bedre, end det nuværende middel på markedet, Gattex, der skal injiceres dagligt mod korttarmssyndrom.
Der er tale om en lidelse, hvor patientens tarm ikke kan optage næringsstoffer og energi i tilstrækkelige mængder, eksempelvis fordi store dele af tyndtarmen er fjernet efter operation, eller fordi tarmen virker utilstrækkeligt efter strålebehandling.
Patienterne har derfor behov for at få tilført ernæring via et drop i blodbanen, såkaldt parenteral ernæring. Med Glepaglutid kan mængden dog nedsættes, og nogle gange kan antallet af gange, hvor der er behov for parenteral ernæring, også reduceres.
Endnu er Glepaglutid og Gattex ikke målt op mod hinanden, men Adam Steensberg glæder sig over, at hele ni patienter, der fik Glepaglutid efter 24 ugers behandling helt kunne stoppe med at få tilført næring via drop. Det tilsvarende tal i studier af Gattex er ifølge Adams Steensberg nul.
Ifølge Jefferies estimater står Zealand med et lægemiddel, der vil kunne sælge for op mod 580 mio. dollar om året, og børshuset regner med, at det kan give anledning til en partneraftale i milliardklassen målt i kroner.
Selv vil Zealand gå efter en aftale, der både giver et stort beløb her og nu, men også indeholder en stor gulerod.
- Det er helt klart vigtigt for mig, at vi får en aftale, hvor der er en stor "upside", men når det er sagt, er det også vigtigt at få en partner, der er maksimalt committet, så jeg kan ikke forestille mig et scenarie, hvor der ikke er en meget stor forudbetaling. Vi kan så måske være klar til at betale nogle af de penge tilbage ind i samarbejdet, siger Adam Steensberg.
.\˙ MarketWire
7/10 2022 09:02 ProInvestorNEWS 0106763 Zealand Pharma completes registration of capital e
Company announcement - No. 45 / 2022
Zealand Pharma completes registration of capital increase
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA, JAPAN OR SOUTH AFRICA, EXCEPT AS PERMITTED BY APPLICABLE LAW.
THIS ANNOUNCEMENT IS NOT AN OFFER OF SECURITIES FOR SALE IN THE UNITED STATES AND THE SECURITIES REFERRED TO HEREIN MAY NOT BE OFFERED OR SOLD IN THE UNITED STATES ABSENT REGISTRATION EXCEPT PURSUANT TO AN EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS OF THE U.S. SECURITIES ACT; ANY PUBLIC OFFERING OF SUCH SECURITIES TO BE MADE IN THE UNITED STATES WILL BE MADE BY MEANS OF A PROSPECTUS THAT MAY BE OBTAINED FROM THE ISSUER, WHICH WOULD CONTAIN DETAILED INFORMATION ABOUT THE COMPANY AND MANAGEMENT, AS WELL AS FINANCIAL STATEMENTS.
Zealand has today completed and registered a capital increase of 4,975,000 new shares
Copenhagen, Denmark, 7 October 2022 - Further to the company announcements no. 43 and 44 / 2022, Zealand Pharma A/S ("Zealand") (Nasdaq: ZEAL), (CVR-no. 20 04 50 78), a biotechnology company focused on the discovery and development of innovative peptide-based medicines, announces that it has today, as part of completion of a directed issue and private placement (the "Offering"), registered with the Danish Business Authority, the capital increase of approx. DKK 786 million, divided into 4,975,000 ordinary shares (the "New Shares").
Following the registration of the New Shares with the Danish Business Authority, Zealand's share capital amounts to DKK 51,513,186 divided into 51,513,186 shares with a nominal value of DKK 1 each.
The New Shares rank pari passu with Zealand's existing shares and carry the same dividend and other rights. Each New Share carries one vote at Zealand's general meetings. Zealand only has one class of shares.
The New Shares have been issued under a temporary ISIN code and are expected to be admitted to trading on Nasdaq Copenhagen on 10 October 2022 in Zealand's permanent ISIN code DK0060257814. The temporary ISIN code is expected to be merged with the permanent ISIN code on 11 October 2022.
The amendments to Zealand's articles of association required by the capital increase have been registered today with the Danish Business Authority.
Managers and legal counsels:
Danske Bank A/S, Goldman Sachs International and Nordea Danmark, Filial af Nordea Bank Abp, Finland are acting as joint global coordinators and joint bookrunners in the Offering, and Kempen & Co is acting as co-lead manager in the Offering (the joint global coordinators and the co-lead manager are jointly referred to as the "Managers").
Plesner and Cooley LLP are acting as Danish and U.S. legal advisors respectively to Zealand. Kromann Reumert is acting as legal advisor to the Managers.
Contacts:
Zealand Pharma
Anna Krassowska, Vice President, Investor Relations & Corporate Communications
AKrassowska@zealandpharma.com
Lykke Rømer, Vice President and Interim Chief Financial Officer
LRomer@zealandpharma.com
Adam Steensberg, President and Chief Executive Officer
ASteensberg@zealandpharma.com
Company announcement - No. 45 / 2022
Zealand Pharma completes registration of capital increase
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA, JAPAN OR SOUTH AFRICA, EXCEPT AS PERMITTED BY APPLICABLE LAW.
THIS ANNOUNCEMENT IS NOT AN OFFER OF SECURITIES FOR SALE IN THE UNITED STATES AND THE SECURITIES REFERRED TO HEREIN MAY NOT BE OFFERED OR SOLD IN THE UNITED STATES ABSENT REGISTRATION EXCEPT PURSUANT TO AN EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS OF THE U.S. SECURITIES ACT; ANY PUBLIC OFFERING OF SUCH SECURITIES TO BE MADE IN THE UNITED STATES WILL BE MADE BY MEANS OF A PROSPECTUS THAT MAY BE OBTAINED FROM THE ISSUER, WHICH WOULD CONTAIN DETAILED INFORMATION ABOUT THE COMPANY AND MANAGEMENT, AS WELL AS FINANCIAL STATEMENTS.
Zealand has today completed and registered a capital increase of 4,975,000 new shares
Copenhagen, Denmark, 7 October 2022 - Further to the company announcements no. 43 and 44 / 2022, Zealand Pharma A/S ("Zealand") (Nasdaq: ZEAL), (CVR-no. 20 04 50 78), a biotechnology company focused on the discovery and development of innovative peptide-based medicines, announces that it has today, as part of completion of a directed issue and private placement (the "Offering"), registered with the Danish Business Authority, the capital increase of approx. DKK 786 million, divided into 4,975,000 ordinary shares (the "New Shares").
Following the registration of the New Shares with the Danish Business Authority, Zealand's share capital amounts to DKK 51,513,186 divided into 51,513,186 shares with a nominal value of DKK 1 each.
The New Shares rank pari passu with Zealand's existing shares and carry the same dividend and other rights. Each New Share carries one vote at Zealand's general meetings. Zealand only has one class of shares.
The New Shares have been issued under a temporary ISIN code and are expected to be admitted to trading on Nasdaq Copenhagen on 10 October 2022 in Zealand's permanent ISIN code DK0060257814. The temporary ISIN code is expected to be merged with the permanent ISIN code on 11 October 2022.
The amendments to Zealand's articles of association required by the capital increase have been registered today with the Danish Business Authority.
Managers and legal counsels:
Danske Bank A/S, Goldman Sachs International and Nordea Danmark, Filial af Nordea Bank Abp, Finland are acting as joint global coordinators and joint bookrunners in the Offering, and Kempen & Co is acting as co-lead manager in the Offering (the joint global coordinators and the co-lead manager are jointly referred to as the "Managers").
Plesner and Cooley LLP are acting as Danish and U.S. legal advisors respectively to Zealand. Kromann Reumert is acting as legal advisor to the Managers.
Contacts:
Zealand Pharma
Anna Krassowska, Vice President, Investor Relations & Corporate Communications
AKrassowska@zealandpharma.com
Lykke Rømer, Vice President and Interim Chief Financial Officer
LRomer@zealandpharma.com
Adam Steensberg, President and Chief Executive Officer
ASteensberg@zealandpharma.com
